<DOC>
	<DOC>NCT02283788</DOC>
	<brief_summary>A randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover trial to evaluate the effect of eslicarbazepine acetate on cardiac repolarization in healthy adult men and women</brief_summary>
	<brief_title>Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization</brief_title>
	<detailed_description>The purpose of this randomized, double-blind, placebo-controlled and open label active-controlled, 4 period crossover study was to evaluate the effect of therapeutic and supra-therapeutic doses of eslicarbazepine acetate on the placebo corrected time-matched change from baseline using individually corrected QT (QTcI) interval durations in adult healthy volunteers.</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Be a healthy male or female 18 to 45 years of age. Women were required to be postmenopausal (more than 12 months since last period); surgically sterile (hysterectomy or tubal ligation at least 6 months prior to enrollment); using an intrauterine device; or double barrier (i.e. diaphragm or spermicide plus male condom) nonhormonal contraceptive therapy for the duration of the trial and were required to have a negative pregnancy test at screening and upon each checkin to the study facility. Have a BMI within the range of 1830 kg/m2. Be able to communicate effectively with the study personnel. Have no significant disease or abnormal laboratory values as determined by medical history, physical examination or laboratory evaluations, conducted at the screening visit and on each admission to the clinic. Have a normal 12lead electrocardiogram, without any clinically significant abnormalities of rate, rhythm or conduction. Be nonsmokers defined as not having smoked in the past 6 months. Be adequately informed of the nature and risks of the study and give written informed consent prior to study entry. Known hypersensitivity or allergy to moxifloxacin, eslicarbazepine acetate or related compounds such as carbamazepine, oxcarbazepine, or licarbazepine. Women who were pregnant or breast feeding. Any disease or condition (medical or surgical) which, in the opinion of the investigator, might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or placed the subject at increased risk. A sustained supine systolic blood pressure &gt; 140 mmHg or &lt;100mm Hg or a diastolic blood pressure &gt; 95 mmHg at screening or baseline. A resting ECG heart rate of &lt;50 bpm or &gt;100 bpm.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>